Adjuvant Chemo in High-Risk Localized Prostate Cancer

Video
Conference|American Society of Clinical Oncology Annual Meeting (ASCO)

This video examines a phase III study that tested the addition of docetaxel and prednisone to standard therapy as adjuvant treatment for men with high-risk localized prostate cancer.

In this video, Howard M. Sandler, MD, of Cedars-Sinai Medical Center in Los Angeles, discusses a phase III study that tested the addition of docetaxel and prednisone to standard therapy as adjuvant treatment for men with high-risk localized prostate cancer.

Dr. Sandler presented results of the trial at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Recent Videos
Hosts Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, discuss presentations at ESMO 2025 that may impact bladder, kidney, and prostate cancer care.
Mandating additional immunotherapy infusions may help replenish T cells and enhance tumor penetration for solid tumors, including GI malignancies.
A novel cancer database may assist patients determine what clinical trials they are eligible to enroll on and identify the next best steps for treatment.
Receiving information regarding tumor-associated antigens or mutational statuses from biopsies may help treatment selection in GI malignancies.
An easy-to-access database allows one to see a patient’s cancer stage, prior treatment, and survival outcomes in a single place.
Better defining which patients with GI cancers are preferred candidates for adoptive cellular therapies may help optimize outcomes.
A consolidated database may allow providers to access information on a patient’s prior treatments and genetic abnormalities all in 1 place.
A study presented at ASTRO 2025 evaluated the feasibility of using a unified cancer database to consolidate information gathered across 14 institutions.
Related Content
T-DXd significantly improved iDFS compared with T-DM1 across various patient subgroups in high-risk, HER2-positive primary breast cancer with residual invasive disease.

Adjuvant T-DXd Improves Efficacy vs T-DM1 in HER2-Positive Breast Cancer

Ashling Wahner
October 18th 2025
Article

T-DXd significantly improved iDFS compared with T-DM1 across various patient subgroups in high-risk, HER2-positive primary breast cancer with residual invasive disease.

Experts highlight anticipated sessions at the 2025 ESMO Congress, including those on the PSMAddition and EV-303 trials.

Exploring the ESMO 2025 Presentations That May Shift GU Oncology

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
October 16th 2025
Podcast

Experts highlight anticipated sessions at the 2025 ESMO Congress, including those on the PSMAddition and EV-303 trials.

Results from the phase 3 KEYNOTE-B96 trial showed favorable results with pembrolizumab-based therapy in this ovarian cancer population.

Pembrolizumab Combo Significantly Improves PFS/OS in Recurrent PROC

Tim Cortese
October 18th 2025
Article

Results from the phase 3 KEYNOTE-B96 trial showed favorable results with pembrolizumab-based therapy in this ovarian cancer population.

A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

Navigating AE Management for Cellular Therapy Across Hematologic Cancers

Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
August 11th 2025
Podcast

A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

BNT111 Plus Cemiplimab Yields Positive Efficacy in PD-(L)1-Relapsed/Refractory Melanoma

BNT111 Plus Cemiplimab Yields Positive Efficacy in PD-(L)1-Relapsed/Refractory Melanoma

Caroline Seymour
October 18th 2025
Article

BNT111 combined with cemiplimab showed promising efficacy in treating PD-(L) PD-L1-relapsed/refractory melanoma, achieving an 18.1% objective response rate.

Novel Agent Meets End Points in COMPETE Trial for GEP-NETs

Novel Agent Meets End Points in COMPETE Trial for GEP-NETs

Paige Britt
October 18th 2025
Article

ITM-11 showed superior PFS and ORR compared with everolimus in patients with gastroenteropancreatic neuroendocrine tumors.